Norris Medicines Limited has scheduled a board meeting for Saturday, 14th November, 2026, to be held at the company's registered office at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002.
The primary agenda items include:
- Consideration and approval of Un-audited Financial Results for the quarter and half year ended 30th September, 2026
- Consideration and approval of the Limited Review Report for the same period
- Any other business with permission of the Chair
The company has confirmed that the Trading Window for dealing in securities of the Company has been closed since 1st October, 2026, in accordance with the Company's Code of Conduct for Prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed until forty-eight (48) hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026 on the stock exchange.
The disclosure is made under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and is addressed to BSE Limited.
The document is signed by Vimal Shah, Managing Director (DIN: 01506655), on behalf of Norris Medicines Limited.